Probiotics in Children With Early Childhood Caries
Influence of the Probiotic Streptococcus Salivarius K12 on Dental Health in Children With Early Childhood Caries
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Warsaw, 18 Miodowa Saint
-
Warsaw, Warsaw, 18 Miodowa Saint, Poland, 00-246
- Recruiting
- Dorota Olczak-Kowalczyk
-
Contact:
- Dorota Olczak-Kowalczyk, Ass.Prof.
- Phone Number: +48 22 502 20 31
- Email: pedodoncja@wum.edu.pl
-
Principal Investigator:
- Anna Turska-Szybka, Phd, MD
-
Principal Investigator:
- Dorota Olczak-Kowalczyk, Ass.Prof.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- generally healthy children aged 3-6;
- recognized caries of early childhood, dmf> 1,
- lack of active caries and inflammation of the mouth
- CFU> 105 / ml Streptococcus mutans
- a minimum of one-month period from: the last antibiotic therapy, probiotic use, professional fluoride prophylaxis or supervised tooth brushing with fluoride preparations, the use of fluoride toothpaste, not using xylitol, written consent of parents / legal guardians for participation in research.
Exclusion Criteria:
chronic diseases and chronically taken medicines in the past,
- planned change of residence during the year,
- age below 3 and above 6 years,
- healthy teeth, dmf = 0,
- CFU <105 / ml Streptococcus mutans
- Patient during antibiotic therapy, probiotic use, professional fluoride prophylaxis or supervised tooth brushing with fluoride preparations
- no toothpaste with fluoride
- using xylitol
- lack of written consent of parents / legal guardians for participation in research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotics
A half of the participants will be randomly allocated to the probiotics group.
They will receive probiotic lozenge before falling asleep for12 weeks.
They will receive hygienic and dietetic instructions.
examination will be conducted before study and after 12 weeks.
|
the participants will receive probiotic lozenge before falling asleep for 12 weeks. the participants will receive dietetic and hygienic instructions |
|
Sham Comparator: CONTROL
no intervention
|
No intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changing the amount of carcinogenic bacteria Streptococcus mutans in intervention group based on bacterial test counting number of Colony Forming Units
Time Frame: 12 weeks
|
During control test saliva will be applied to the medium for identification and detailed quantification of Streptococcus mutans bacteria.
After the incubation, the number of bacteria will be expressed - taking into account the degree of saliva dilution - as the number of colony-forming unit (CFU) in 1 ml of saliva.
colony forming unit CFU in intervention and control groups.
Bacterial tests will be used to assess this outcome measure.
We expect decrement of amount of cariogenic bacteria in intervention group
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- KB/202/2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dietary Supplement
-
NCT04088617CompletedDietary Supplement: Ketone Supplement | Dietary Supplement: Placebo
-
NCT05880186Completed
-
NCT03395119Completed
-
NCT07127796Not yet recruiting
-
NCT07129863CompletedDietary Supplement | Sports Performance
-
NCT04210531CompletedDietary Supplement | Sport Performance
-
NCT07474753CompletedExercise | Dietary Supplement
-
NCT05337527CompletedPlacebo | Dietary Supplement
-
NCT05210244CompletedDietary Supplement | Sport Performance
Clinical Trials on No intervention
-
NCT06980844Not yet recruitingInterstitial Lung Disease
-
NCT02746445Completed
-
NCT05345054CompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social Behavior
-
NCT01923415CompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, Discoid
-
NCT06134739RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | Ablation
-
NCT03305484CompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein Staining
-
NCT06686342RecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in Vitro
-
NCT03385811UnknownIntention to Stay, Turnover Behavior